Published in Mol Cell Biol on August 28, 2006
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med (2010) 5.76
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell (2007) 5.09
Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol (2009) 3.63
The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat Immunol (2008) 2.12
Smac mimetics and TNFalpha: a dangerous liaison? Cell (2007) 1.53
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
NEMO/IKKgamma regulates an early NF-kappaB-independent cell-death checkpoint during TNF signaling. Cell Death Differ (2009) 1.27
Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem (2011) 1.23
Signaling flux redistribution at toll-like receptor pathway junctions. PLoS One (2008) 1.12
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther (2011) 1.09
Dot1a contains three nuclear localization signals and regulates the epithelial Na+ channel (ENaC) at multiple levels. Am J Physiol Renal Physiol (2010) 1.02
Alix and ALG-2 are involved in tumor necrosis factor receptor 1-induced cell death. J Biol Chem (2008) 1.02
Membrane-bound Fas ligand requires RIP1 for efficient activation of caspase-8 within the death-inducing signaling complex. J Immunol (2009) 1.01
The role of TRADD in death receptor signaling. Cell Cycle (2012) 1.00
CD95 stimulation results in the formation of a novel death effector domain protein-containing complex. J Biol Chem (2008) 0.98
Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion. Recent Pat Anticancer Drug Discov (2011) 0.97
The role of TRADD in TRAIL-induced apoptosis and signaling. FASEB J (2010) 0.94
CLIPR-59 regulates TNF-α-induced apoptosis by controlling ubiquitination of RIP1. Cell Death Dis (2012) 0.93
TNFalpha-induced macrophage death via caspase-dependent and independent pathways. Apoptosis (2009) 0.91
Moxibustion inhibits apoptosis and tumor necrosis factor-alpha/tumor necrosis factor receptor 1 in the colonic epithelium of Crohn's disease model rats. Dig Dis Sci (2012) 0.91
TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res (2008) 0.91
Molecular crosstalk between apoptosis, necroptosis, and survival signaling. Mol Cell Oncol (2015) 0.91
Surviving apoptosis: life-death signaling in single cells. Trends Cell Biol (2015) 0.90
TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL. PLoS One (2010) 0.89
Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells. Int J Cancer (2009) 0.89
Monocyte chemoattractant protein-1 (MCP-1) regulates macrophage cytotoxicity in abdominal aortic aneurysm. PLoS One (2014) 0.89
The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. Cell Death Dis (2012) 0.89
The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas. J Cell Biol (2011) 0.85
Regulating the balance between necroptosis, apoptosis and inflammation by inhibitors of apoptosis proteins. Immunol Cell Biol (2016) 0.82
Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J Virol (2008) 0.82
Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells. J Virol (2012) 0.82
Computational cell fate modelling for discovery of rewiring in apoptotic network for enhanced cancer drug sensitivity. BMC Syst Biol (2015) 0.80
Cell fate decisions regulated by K63 ubiquitination of tumor necrosis factor receptor 1. Mol Cell Biol (2014) 0.79
TNF-related apoptosis-inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation. FASEB J (2015) 0.78
Bid signal pathway components are identified in the temporal cortex with Parkinson disease. Neurology (2012) 0.78
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death. J Biomed Sci (2012) 0.77
Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer (2008) 0.77
EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins. J Neurooncol (2009) 0.77
A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma. Oncotarget (2011) 0.77
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem (2014) 0.76
Activation of TRAIL-DR5 pathway promotes sensorineural degeneration in the inner ear. Aging Cell (2016) 0.75
TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors. Cell Death Dis (2016) 0.75
Reduced internalization of TNF-ɑ/TNFR1 down-regulates caspase dependent phagocytosis induced cell death (PICD) in neonatal monocytes. PLoS One (2017) 0.75
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell (2003) 11.07
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell (1996) 8.89
The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell (1995) 8.80
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol (2000) 8.49
Tumor necrosis factor signaling. Cell Death Differ (2003) 8.48
TNF-R1 signaling: a beautiful pathway. Science (2002) 7.98
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity (1998) 7.35
A unified model for apical caspase activation. Mol Cell (2003) 6.12
Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity (1998) 6.07
TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity (1996) 5.45
FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science (1998) 5.29
NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol (2001) 4.55
Apoptosis control by death and decoy receptors. Curr Opin Cell Biol (1999) 4.54
Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev (1999) 4.39
RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J (1996) 4.33
An induced proximity model for caspase-8 activation. J Biol Chem (1998) 4.18
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Death receptor-induced cell killing. Cell Signal (2004) 3.67
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity (2004) 3.26
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity (2000) 2.93
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev (2002) 2.31
Insights into the regulatory mechanism for caspase-8 activation. Mol Cell (2003) 2.01
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity (1999) 1.86
The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol (2003) 1.83
The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep (2003) 1.73
Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis. J Biol Chem (2003) 1.37
NF-kappaB protects macrophages from lipopolysaccharide-induced cell death: the role of caspase 8 and receptor-interacting protein. J Biol Chem (2005) 1.19
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (2002) 1.12
Carbon monoxide promotes Fas/CD95-induced apoptosis in Jurkat cells. J Biol Chem (2004) 1.10
Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J Biol Chem (2001) 0.97
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Overview of cell death signaling pathways. Cancer Biol Ther (2005) 4.22
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Critical role for Daxx in regulating Mdm2. Nat Cell Biol (2006) 2.96
TRAIL and apoptosis induction by TNF-family death receptors. Oncogene (2003) 2.75
P53 and radiation responses. Oncogene (2003) 2.52
Retracted GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell (2009) 2.30
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol (2013) 2.06
Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther (2003) 1.92
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 1.84
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol (2003) 1.83
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80
Tissue-specific induction of p53 targets in vivo. Cancer Res (2002) 1.79
TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets (2010) 1.65
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem (2004) 1.59
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol (2008) 1.58
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell (2004) 1.54
Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol (2003) 1.54
Restoration of p53 to limit tumor growth. Curr Opin Oncol (2008) 1.52
The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle (2002) 1.45
Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget (2011) 1.43
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest (2008) 1.41
Mcl-1: a gateway to TRAIL sensitization. Cancer Res (2008) 1.41
Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis (2009) 1.40
Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther (2005) 1.38
Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther (2004) 1.38
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther (2008) 1.34
Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther (2003) 1.32
Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res (2009) 1.31
Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A (2002) 1.30
Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem (2004) 1.29
Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res (2004) 1.28
BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol (2002) 1.28
Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle (2007) 1.28
Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol (2005) 1.27
Current strategies to target p53 in cancer. Biochem Pharmacol (2010) 1.26
Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol (2008) 1.25
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol (2003) 1.25
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (2002) 1.24
Restoring p53-dependent tumor suppression. Cancer Biol Ther (2003) 1.24
Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem (2011) 1.23
An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. Biomicrofluidics (2012) 1.22
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res (2004) 1.22
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther (2007) 1.22
Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep (2010) 1.21
Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res (2006) 1.20
The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle (2009) 1.18
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther (2006) 1.16
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A (2003) 1.16
What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther (2006) 1.16
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (2015) 1.14
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet (2003) 1.14
Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis (2003) 1.13
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (2002) 1.12
Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A (2004) 1.10
p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res (2006) 1.09
Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol (2008) 1.08
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (2011) 1.07
ERK and MDM2 prey on FOXO3a. Nat Cell Biol (2008) 1.04
Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther (2005) 1.04
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther (2013) 1.03
Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res (2013) 1.02
Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther (2005) 1.02
Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol (2004) 1.02
Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol Ther (2003) 1.02
Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets (2015) 1.02
CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem (2006) 1.01
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab (2005) 1.01
TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle (2008) 1.01
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem (2003) 1.00
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med (2011) 0.99
Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle (2007) 0.99
CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle (2013) 0.98
Multispectral fluorescence imaging. J Nucl Med (2009) 0.98
Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene (2002) 0.98
The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle (2011) 0.97
IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol Ther (2007) 0.97
Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther (2003) 0.97
Clinical implication of p53 mutation in lung cancer. Mol Biotechnol (2003) 0.96
Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem (2003) 0.96
p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol (2007) 0.96
Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther (2006) 0.95
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res (2011) 0.94
Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol Ther (2011) 0.94
Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget (2014) 0.94
Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther (2008) 0.93
DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res (2008) 0.93
Targeting p53 by PTD-mediated transduction. Trends Biotechnol (2004) 0.93
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther (2011) 0.93
Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res (2008) 0.93
EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am J Physiol Gastrointest Liver Physiol (2005) 0.92